```html

Kawasaki Syndrome – Comprehensive Medical Guide

Overview

Kawasaki disease (KD), also called Kawasaki syndrome, is an acute, self‑limited vasculitis that primarily affects medium‑sized arteries, especially the coronary arteries. It is the leading cause of acquired heart disease in children in developed countries.

• Typical age: Children < 5 years old (peak 1–2 years). Rare in infants < 6 months and adults.
• Gender: Boys are about 1.5–1.8 times more likely to develop KD than girls.
• Incidence: Approximately 19,000 cases are reported annually in the United States (≈ 20 per 100,000 children < 5 years). Highest rates are in East Asian populations (Japan ≈ 300 per 100,000).
• Geography: Worldwide distribution, with seasonal peaks (winter‑spring in temperate zones, summer in tropical regions).

The exact trigger remains unknown, but a combination of genetic susceptibility and an abnormal immune response to an infectious agent is the leading hypothesis.

Symptoms

Kawasaki disease is diagnosed based on a constellation of clinical findings. The classic presentation includes fever lasting ≥ 5 days plus at least four of the five principal features.

Principal clinical features

• Fever: High (often > 39 °C / 102 °F), remittent, unresponsive to antipyretics.
• Conjunctival injection: Bilateral non‑purulent redness of the eyes without discharge.
• Oral changes: Cracked, “strawberry” tongue, red fissured lips, diffuse erythema of the oropharynx.
• Extremity changes:
  • Acute phase – erythema and edema of hands/feet.
  • Subacute phase – periungual desquamation (peeling) beginning around day 10‑14, typically beginning at fingertips.
• Polymorphous rash: Can be maculopapular, erythema multiforme–like, or erythema marginatum‑type; often starts on trunk and spreads.
• Cervical lymphadenopathy: Usually unilateral, > 1.5 cm, firm, non‑suppurative.

Other (sometimes) associated findings

• Joint pain or swelling (arthralgia/arthritis)
• Abdominal pain, vomiting, or diarrhea
• Irritability or lethargy, especially in infants
• Cardiac murmurs from coronary artery involvement
• Peripheral neuropathy (rare)

Causes and Risk Factors

Despite intensive research, no single pathogen has been definitively proven to cause Kawasaki disease. Current thinking emphasizes an aberrant immune response in genetically predisposed children after exposure to an infectious trigger.

Potential contributors

• Infectious agents: Viral (e.g., adenovirus, rhinovirus) and bacterial (Streptococcus, Staphylococcus) agents have been detected, but none meet Koch’s postulates.
• Genetic susceptibility:
  • Polymorphisms in ITPKC, CASP3, FCGR2A, and HLA‑related genes are linked to higher risk.
  • Higher incidence in children of Asian ancestry supports a genetic component.
• Environmental factors: Seasonal outbreaks suggest airborne or water‑borne agents; climate and pollution may modulate risk.

Who is at higher risk?

• Children < 5 years, especially males.
• Family history of KD or autoimmune disease.
• Certain ethnic groups (Japanese, Korean, Chinese, Pacific Islanders).
• Presence of a recent upper‑respiratory or gastrointestinal infection.

Diagnosis

There is no specific laboratory test for Kawasaki disease; diagnosis is clinical, supported by laboratory and imaging findings.

Clinical criteria

Fever ≥ 5 days + ≥ 4 of the 5 principal features (see Symptoms section). Incomplete or “atypical” KD is diagnosed when fever persists and some classic features are present, but coronary artery abnormalities are demonstrated on echocardiography.

Laboratory clues

• Elevated inflammatory markers: ESR > 40 mm/hr, CRP > 3 mg/dL.
• Leukocytosis (white blood cells > 12 000/µL) with neutrophil predominance.
• Normocytic anemia.
• Thrombocytosis (platelets > 450 000/µL) after day 7.
• Elevated liver enzymes, hypoalbuminemia, sterile pyuria.

Imaging & other tests

• Echocardiography: First‑line cardiac imaging; looks for coronary artery dilation/aneurysm, pericardial effusion, valvular regurgitation.
• Electrocardiogram (ECG): May show ST‑segment changes or arrhythmias.
• Chest X‑ray: To assess heart size in severe cases.
• Blood cultures: To rule out bacterial sepsis when fever is high.

Treatment Options

Prompt therapy (ideally within the first 10 days of illness) dramatically reduces the risk of coronary artery complications.

First‑line therapy

• Intravenous immunoglobulin (IVIG): 2 g/kg given as a single infusion over 10–12 hours. Reduces fever within 24–48 h in > 80 % of patients.
• Aspirin: High‑dose (80–100 mg/kg/day) divided every 6 h during the acute febrile phase, then low‑dose (3–5 mg/kg/day) for antiplatelet effect until 6–8 weeks after disease onset (or longer if coronary aneurysms persist).

Adjunctive / refractory therapy

≈ 10‑20 % of children have persistent or recrudescent fever after initial IVIG. Options include:

• Second dose of IVIG (2 g/kg).
<
• Corticosteroids (e.g., methylprednisolone 30 mg/kg IV once daily for 1–3 days, then oral taper).
• Biologic agents:
  • Infliximab (anti‑TNFα) – 5 mg/kg IV.
  • Etanercept or Anakinra (IL‑1 blockade) in select centers.
• Other immunomodulators (e.g., cyclosporine) for rare, resistant cases.

Lifestyle & supportive care

• Hydration and nutrition – maintain oral intake; consider nasogastric feeds if vomiting.
• Fever control – acetaminophen can be used alongside aspirin for comfort.
• Monitoring – daily temperature and cardiac assessment during hospitalization.

Living with Kawasaki Syndrome

Even after the acute episode resolves, families need a structured plan to monitor heart health and support normal childhood development.

Follow‑up schedule

• 2 weeks after onset: Repeat echocardiogram to assess coronary artery changes.
• 6–8 weeks: Second echocardiogram and ECG; decide duration of low‑dose aspirin.
• 6 months–1 year: Additional imaging if aneurysms were present.

Daily management tips

• Maintain the aspirin regimen as prescribed; do not stop abruptly without medical advice.
• Encourage regular physical activity once fever resolves, but avoid strenuous exertion if coronary aneurysms are noted.
• Watch for signs of thrombosis (e.g., sudden chest pain, shortness of breath) and report immediately.
• Keep a health‑record booklet with all imaging reports, medication lists, and emergency contacts.
• School reintegration: Most children can return to school after fever subsides and they feel well; inform teachers about the need for occasional medication administration.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, certain measures may lower risk or mitigate severity:

• Prompt treatment of upper‑respiratory infections and good hand hygiene to reduce potential triggers.
• Early medical evaluation for any child with persistent high fever and rash.
• Genetic counseling for families with multiple affected members (rare).

Complications

When untreated or inadequately treated, Kawasaki disease can lead to serious, sometimes life‑threatening, outcomes.

• Coronary artery aneurysms: Occur in ~25 % of untreated patients; risk of thrombosis, myocardial infarction, or sudden cardiac death.
• Myocarditis or pericarditis: Can cause heart failure.
• Valvular dysfunction: Most commonly aortic root dilation or mitral regurgitation.
• Peripheral artery stenosis: Rare, may affect limbs.
• Long‑term sequelae: Persistent coronary artery disease requiring lifelong cardiology care, antiplatelet therapy, or even revascularization.

When to Seek Emergency Care

References

• Mayo Clinic. Kawasaki disease. Updated 2023.
• American Heart Association. Recommendations for the Diagnosis and Treatment of Kawasaki Disease. Circulation. 2022.
• CDC. Kawasaki Disease (Mucocutaneous Lymph Node Syndrome). 2021.
• World Health Organization. Guidelines for Management of Kawasaki Disease. 2020.
• Cleveland Clinic. Kawasaki Disease Overview. 2023.
• Newburger JW, et al. “Kawasaki Disease.” NEJM. 2023;388:1515‑1526.

```